-
DEA pushes forward on rescheduling hydrocodone combination products
WASHINGTON — In what could turn into a significant change of how retail pharmacy supplies hydrocodone combination products, the Drug Enforcement Administration last week published in the Federal Register a Notice of Proposed Rulemaking to move HCPs from Schedule III to Schedule II, as recommended by the assistant secretary for Health of the department of Health and Human Services and as supported by the DEA’s evaluation of relevant data.
-
Dr. Reddy's launches moxifloxacin tablets
HYDERABAD, India — Dr. Reddy's Labs announced the launch of moxifloxacin hydrochloride tablets, the generic version of Avelox tablets, in 400-mg form. The drug is available in bottle counts of 30.
Avelox tablets had U.S. sales of approximately $195 million for the 12 months ending in December 2013, according to IMS Health.